Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | MET | P08581 | 4/20 | 0.51 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372087 | 0.85 | MET (0.57) | ACHEBACE1FGFR2PDGFRAKDR | |
| SCHEMBL371581 | 0.84 | FGFR2 (0.54) | FGFR2PDGFRAPDGFRBKDRMET | |
| SCHEMBL20525754 | 0.82 | ALK (0.46) | ACHEBACE1MAPT | |
| SCHEMBL2864532 | 0.81 | MET (0.63) | FGFR2PDGFRAKDRMETKIT | |
| SCHEMBL4465629 | 0.78 | FGFR2 (0.68) | FGFR2PDGFRAPDGFRBKDRMET | |
| SCHEMBL2858013 | 0.78 | SYK (0.56) | FGFR2PDGFRAPDGFRBKDRMET | |
| SCHEMBL31060325 | 0.78 | FGFR2 (0.78) | FGFR2PDGFRAPDGFRBKDRKIT | |
| SCHEMBL17117826 | 0.78 | FGFR2 (0.78) | FGFR2PDGFRAPDGFRBKDRKIT | |
| SCHEMBL5825390 | 0.77 | PDGFRA (0.71) | PDGFRAKDRMETKIT | |
| SCHEMBL10288440 | 0.77 | PDGFRA (0.66) | FGFR2PDGFRAKDRMETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | claimed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | claimed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | claimed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | claimed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | claimed |
| US-20120184523-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2012-07-19 | — | — | US | claimed |
| US-20110077233-A1 | C-Met Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-03-31 | — | — | US | claimed |
| WO-2009017838-A2 | COMBINATIONS OF JAK-2 INHIBITORS AND OTHER AGENTS | EXELIXIS, INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | claimed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | claimed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ACHE 3149/4885BACE1 2603/4885FGFR2 529/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ACHE 2573/4885BACE1 2075/4885FGFR2 590/4885 |
| US-20120184523-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | ACHE 3149/4885BACE1 2603/4885FGFR2 529/4885 |
| US-20110077233-A1 | C-Met Modulators and Method of Use | FLT4, MET, FLT1 | ACHE 3149/4885BACE1 2603/4885FGFR2 529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.